INTRODUCTION
Now-a-day, chronic lung diseases are among the most prevalent diseases causing disability and mortality, among which asthma, as one of the most common diseases, has signifi cant prevalence and incidence. Asthma is a chronic infl ammatory disease of the airways that leads to airway narrowing through the processes of infl ammation and smooth muscle contraction in airway walls (bronchoconstriction). Symptoms include Study of the prevalence of asthma symptoms, according to a meta-analysis on the country-level which was performed by Heidarnia et al. between 1378 and 1383 , showed that the prevalence of the symptoms is diff erent in children in diff erent regions of the country and varies between 2.7% in Kerman and 35.4% in Tehran. According to this study, the mean prevalence of asthma symptoms across the country were obtained in 13.14% (95% confidence interval [CI]: 9.97-16.30%). [5] Formoterol and salmeterol are two long-acting β2-agonist given by inhalation, with bronchodilating effects lasting for at least 12 h after a single administration. [6, 7] Both of these drugs have become valuable complements in the regular treatment of asthmatic patients who are not satisfactorily controlled with inhaled corticosteroids. [8] Formoterol has a faster onset of action within 5 min compared with salmeterol that has a slower onset of action within 15-20 min. [9] In today's world where there are limited resources to meet unlimited health care needs of the people, the importance of informed decision-making with the least chance of error in the health sector and the lack of resources in our country is essential, because the use of a new drug in the treatment can be accompanied by various complications and diff erent tolerance levels, and signifi cant price diff erence can be found between the use of existing drugs and a new drug. This study is conducted to evaluate the safety and eff ectiveness of formoterol versus salmeterol in the treatment of patients with asthma.
MATERIALS AND METHODS
We conducted a systematic review and meta-analysis. Diff erent phases of the study included searching, screening, and selecting of studies, extracting data and data cleaning and analyzing.
Search strategy
To retrieve related studies, we used a sensitive search strategy in medical citation databases including, Cochran Library, PubMed, Scopus, PsycInfo, and IranMedex. In addition, we performed manual search of the databases that record randomized clinical trials, conference proceedings, and journals related to asthma such as American Academy of Allergy, Asthma and Immunology, American Thoracic Society, Asia Pacific Society of Respirology, British Thoracic Society Winter Meeting, and other journal such as Allergology International, Clinical Drug Investigation, American Journal of Respiratory and Critical Care Medicine, Journal of Asthma, and Canadian Respiratory Journal. Also, we checked health.govandopen.gov in case of complication of medications. In order to fi nd the dissertation proposal, Dissertation Abstracts Online was searched, and then an alert was generated in Google Scholar during the execution of new articles to be achieved.
In search protocol, we were used in the combination of the MeSH terms "formoterol," "salmeterol" and "asthma."
The last search in databases was performed on July 10, 2012. Search was updated on February 24, 2013 but new records were not found.
The following search strategy was conducted for library Cochrane and then adapted to the other resources. We did not limit our search to a certain language or time period to avoid missing possibly related works. Besides, we factored in manual reference checking and citation tracking of related paper. All the studies inserted in the EndNoteX4 Thomson Reuters's so ware and duplicates were excluded, and then the titles and abstracts were reviewed based on inclusion and exclusion criteria.
Inclusion criteria
Clinical trials that have designed as crossover or parallel studies or have conducted as double-blind or open, or have compared adult asthmatic patients treated with formoterol and salmeterol, were entered into the study.
Exclusion criteria
The following were excluded from the study: Trials that have been performed in vitro and trials that have examined the patients suffering from diseases with differential diagnosis of asthma (such as chronic obstructive pulmonary disease, exercise-induced asthma, nocturnal asthma, and asthma in children), the use of formoterol in combination with other drugs such as budesonide, and the use of salmeterol in combination with other drugs such as fl uticasone.
Study selection
Full-text of the relevant studies was critically appraised for eligibility criteria by two researchers independently. The third colleague assessed the papers in case of disagreement. Formoterol unrelated and duplicated articles were excluded based on title and abstract. Flow diagram of studies included in the systematic review is shown in Figure 1 .
Quality assessment
Studies that met the inclusion criteria of our review were independently evaluated by two researchers in a qualitative manner, according to Cochran indices. Also we used the Jadad quality assessment scale (JADAD scale) in order for quality assessment.
Although the quality was not used as a case for excluding studies, it was considered in the fi nal conclusion when evaluating the results of studies.
Data synthesis
Data extraction forms were designed for the data extracted from papers, which were checked by the second person. Common outcomes of papers were entered into the RevMan 5.0.1 Cochrane Collaboration's so ware: The outcomes of this study were entered into the "Data Analysis" section of the so ware in a continuous quantitative manner; the sub-outcomes entered the data of related studies; and the mean diff erence and CI (95%) were calculated based on a fi xed-eff ect model. Homogeneity and heterogeneity were evaluated using I 2 and Chi-square tests based on the P value. For the outcomes of homogeneous studies, the metaanalysis data were used in this study while the data were qualitatively reported for the outcomes of heterogeneous studies.
RESULTS
One thousand three hundred and thirty-six of 1536 articles found in this study remained a er removing duplicate cases: Thirty-three studies met the study's inclusion criteria on the basis of title and abstract; and concerning eight articles whose original printed versions were not found, the decision was made based on the titles and abstracts available, according to inclusion and exclusion criteria of the study. Thirteen of 25 studies were excluded, the reason for exclusion are described in Table 1 . At last, 12 studies whose data are listed in Table 2 met the inclusion criteria of the review. Flow diagram of selecting studies is shown in Figure 1 .
The total number of participants in the 12 studies was 1661. The outcomes selected in these studies were forced expiratory volume 1 s (FEV1) and Borg score in two studies, FEV1 in six studies, peak expiratory fl ow (PEF) in one study, episode-free days (EFDs) and quality of life in one study, and PEF and EFDs in one study, as well as FEV1 and PEF in one study. The doses of salmeterol were equal to 50 μg twice daily in nine studies, 100 μg twice daily in one study, both doses in one study, and uncertain dose in one study.
The doses of formoterol were equal to 12 μg twice daily in eight studies, 24 μg twice daily in one study, 12 and 24 μg in one study, doses of 6, 12, and 24 μg in one study, and uncertain dose in one study.
The results of evaluating the homogeneity and heterogeneity of studies, which was done based on I 2 and Chi-square tests according to the P value, are as follows.
Meta-analysis of the outcomes with mean forced expiratory volume 1 s, 12 h a er inhalation of the drug
Three studies of Palmqvist et al., [23] Grembiale et al., [24] Singhania et al. [10] 2008
The study was conducted in a population of children that were not consistent in our study
Lee et al. [11] 2004 Combination of medication was used in the intervention and comparison
Richter et al. [12] 2002 Asthma due to exercise has been considered van der Woude et al. [13] 2001 Combination of medication was used in the intervention and comparison
Lipworth et al. [14] 2000
The study was performed on patients with a specifi c genotype
Aziz et al. [15] 1998 Formoterol and salmeterol were not used in this study
Tan et al. [16] 1997 Formoterol and salmeterol were not used in this study
Brambilla et al. [17] 2003 Combination of medication was used in the intervention and comparison van Veen et al. [18] 2003
The effect of these drugs was compared with short-acting drugs
Schermer et al. [19] 2004
The study was conducted in patients with persistent asthma
Politiek et al. [20] 1999 Combination of medication was used in the intervention and comparison
Eryonucu et al. [21] 2005 Effects on heart rate changes were measured Cates and Lasserson [22] 2010
Combination of medication was used in the intervention and comparison and Rabe et al. [25] were included following outcomes. These studies were homogeneous, and meta-analysis was performed (χ 2 = 0.14, P = 0.93, I 2 = 0%). Forest plot of these studies is shown in Figure 2 .
According to the meta-analysis results, mean diff erence was −0.02 (−0.22, 0.18); there is no difference between formoterol 12 μg and salmeterol 50 μg in mean FEV1 at 12 h a er inhalation of medication. According to the JADAD score of studies with this outcome, this lack of diff erence appears to be valid in the mean FEV1.
Meta-analysis of the outcomes with reduced forced expiratory volume 1 s a er inhalation of methacholine
Two studies from van der Woude et al. [26, 27] were included in this analysis. These studies were homogeneous, and metaanalysis was performed (χ 2 = 0.44, P = 0.51, I 2 = 0%). Forest plot of these studies is shown in Figure 3 .
According to the meta-analysis results, this is a signifi cant difference as 5.23 (1.11-9.34 ). Therefore, the use of salmeterol 50 μg a er inhalation of methacholine reduced more the FEV1 than that of formoterol 12 μg; in these two studies, the ratio dosage of formoterol to salmeterol is same and these studies are similar in this regard, so this point has been considered as restitution of this analysis, and these results should be taken with caution. Also, van der Woude study was sponsored by AstraZeneca Company but in another study did not mention the confl ict of interest.
Meta-analysis of outcomes with the number of days without an a ack
Two studies of Ru en-van Mölken et al. [28] and Condemi [29] were included in this analysis. These studies were homogeneous, and meta-analysis was performed (χ² = 0.00, P = 0.96, I 2 = 0%). Forest plot of these studies is shown in Figure 4 .
According to the meta-analysis results, mean difference was 1. 71 (0.19, 3.22) ; this difference is statistically signifi cant, and therefore, the number of days without an attack after use of salmeterol 50 μg is more than that of formoterol 12 μg. However, the difference was not clinically comparable, and their results should be taken with caution because a review of the quality evaluation of these two articles indicates a medium quality. These studies were sponsored by Novartis Company.
Meta-analysis of the outcome with Borg score after inhalation of drugs
Two studies from van der Woude were included in this analysis. [26, 27] These studies were homogeneous, and metaanalysis was performed (χ² =0.05, P = 0.82, I 2 = 0%). Forest plot of these studies is shown in Figure 5 .
According to the meta-analysis results, this difference is not statistically signifi cant as 0.06 (−1.95, 2.06) and, therefore, there is no difference in the score after inhalation of 50 μg salmeterol and 12 μg formoterol, in these two studies, the ratio dosage of formoterol to salmeterol is same and two studies are similar in this regard, so this point has been considered as restitution of this analysis, and these results should be taken with caution. Also, van der Woude was sponsored by 
DISCUSSION
According to the study result, there was no difference found between salmeterol (12 μg) and formoterol (50 μg) in two meta-analyses, and in two other meta-analyses, the results were also in favor of salmeterol (50 μg). Due to their heterogeneous nature, the two outcomes of FEV1 30-60 min after inhalation of medication and morning PEF after inhalation of medication had no meta-analysis capabilities, whose results were reported qualitatively. In both meta-analyses, there were two studies where, for each outcome, they were in favor of the intervention group (formoterol 12 μg) in one study and in favor of the control group (salmeterol 50 μg) in another study. There is also evidence about the safety and effectiveness of formoterol and salmeterol that are as follows.
The complaints observed in the two drug groups of salmeterol and formoterol were similar in the studies by Campbell and Ru en-van the la er of which was funded by the Novartis Corporation.
[28] Condemi's study, which was funded by the Novartis Corporation, showed that the complications of upper respiratory tract infection, aggravation of asthma, headache, and rhinitis in the formoterol group were more than those in the salmeterol group, while the complications of viral infections, sinusitis, bronchitis, cough, pharyngitis, and pain in the salmeterol group were more than those in the formoterol group. In Nightingale's study, complaints observed in the formoterol group were more than those in the salmeterol group. [30] The most common side complaints reported in the study of Condemi were upper respiratory tract infection, asthma, viral infection, sinusitis, bronchitis, headache, rhinitis, and cough; no deaths were reported in any of the groups. [29] In Campbell's study, in total, 1171 side eff ects were reported during the study (during implementation and duration of treatment) by 390 cases, several of whom had reported more than one adverse complication. In this study, the complications observed in both drug groups were almost identical and statistically insignifi cant. In Nightingale's study, the complications observed are (17 of 35 patients, 49%) in the formoterol group, and (13 of 33 patients, 39%) in the salmeterol group, type of complications is not mentioned in this study; during the study, one patient in the formoterol group had suff ered a transient ischemic a ack. In the study by Ru en-van et al., 11 of 241 patients in the formoterol group and 12 of 241 patients in the salmeterol group have had complications. However, they were not noted in the study. Also, the side eff ects of these drugs were not mentioned in other studies.
Only 2 of the 4 studies where side effects of the drugs have been documented have reported details of the observed complications, and the others had just mentioned the number of complications observed. Brands of formoterol used in the four studies include Novartis in two studies, Oxis in one study, and Foradil in one study; and brands of salmeterol used are GlaxoSmithKline in two studies, Serevent and Glaxo-Wellcome in one study, and Serevent in one study. Formoterol 12 μg and salmeterol 50 μg were prescribed twice daily in all 4 studies. Whereas the duration of use was not mentioned in two studies, in two other Taking salmeterol 50 μg after inhalation of methacholine can reduce more the FEV1 than formoterol 12 μg (P = 0.01, CI = [1.11, 9 .34]). The number of days without an attack after taking salmeterol 50 μg is the more than that after taking formoterol 12 μg (P = 0.03, CI = [0. 19, 3.22] ). In mean FEV1 at 12 h after inhalation of medication, there is no difference between formoterol 12 μg and salmeterol 50 μg (P = 0.82, CI = [−0.22, 0.18]). Also, there is no difference in the score after inhalation of 50 μg salmeterol and 12 μg formoterol (P = 0.956, CI = [−1.95, 2.06]).
In the studies included in the review, there were no signifi cant diff erences between the two drugs, in terms of effi ciency and effi cacy. Furthermore, in the study by Ru envan et al., there was no signifi cant diff erence between the two drugs in terms of outcomes and/or costs, and physicians in each country were advised to use the drug with a lower price, which seems to be in line with the results of this project. [10] Overall, the safety and eff ectiveness of formoterol seem to be not more than those of salmeterol; and compared to formoterol, the administration of salmeterol appears to be benefi cial for patients, because salmeterol is being domestically produced in Iran and is readily available in pharmacies in the country.
Limitation of this study
The weaknesses of this study include lack of access to some databases such as EMBASE, due to the database being closed in Iran and not fi nding the full-text of eight studies that had been conducted on this subject, but there were no published articles about them.
